Skip to search formSkip to main contentSkip to account menu

PF-05082566

Known as: 4-1BB Agonist Monoclonal Antibody PF-05082566, PF-2566 
A fully human, agonistic immunoglobulin (Ig) G2 monoclonal antibody (mAb) targeting 4-1BB (CD137, TNFRSF9), with potential immunostimulating activity… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
4-1BB (CD137, TNFRSF9) is an inducible costimulatory receptor expressed on activated T cells. Clinical trials of two agonist… 
Highly Cited
2017
Highly Cited
2017
Purpose: This phase Ib study (NCT02179918) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of… 
2017
2017
A PHASE I STUDY OF UTOMILUMAB (PF‐ 05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20 NON… 
2016
2016
3002Background: PF-05082566 (PF-2566) is a fully human IgG2 monoclonal antibody (mAb) that binds to human 4-1BB (CD137… 
2015
2015
3004 Background: 4-1BB agonists enhance cytotoxic T-cell and NK cell responses, including antibody-dependent cellular… 
2015
2015
CD137 (4-1BB) is a surface protein initially discovered to mark activated T lymphocytes. However, its broader expression pattern… 
Highly Cited
2012
Highly Cited
2012
Abstract4-1BB (CD137, TNFRSF9) is a costimulatory receptor expressed on several subsets of activated immune cells. Numerous… 
2012
2012
4-1BB (CD137, TNFRSF9) is a costimulatory receptor expressed in an activation induced manner on several subsets of immune cells…